Somewhat O.T. <g>
Looking at some of the Biotech stocks that are selling either below book or below cash/share,or close to it,(<g>)and to their recent reported earnings,insiders & institutional holdings, price to book & price/sales and price to cash/share. (Data obtained from Yahoo Finance)
Not looking at this list from a TA at this posting,(that is why the subject is O.T.<g>)
ABGX: For the six months ended 6/30/02, revenues fell 22% to $23.9 million. Net loss totaled $136.2 million, up from $22.4 million. There was a $72.2 million charge related to impairment of investments, including the Curagen and Immunogen investments.
I-25% Int-81%&B P/B 0.82 P/S 9.65 C/Sh $6.27 P/C 1.01
ACLA: For the six months ended 6/30/02, revenues fell 29% to $1.3 million. Net loss rose 45% to $18.9 million.
I-5%&b Int-29%&S P/B 0.41 P/S 19.70 C/Sh $2.12 P/C 0.71
AGNT: For the six months ended 6/02, net sales rose 46% to $11.5 million. Net loss decreased 13% to $6.3 million.
I-10%&b Int-43%&b P/B 0.23 P/S 0.64 C/Sh $1.65 P/C 0.41
ALKS: For the three months ended 6/30/02, revenues fell 34% to $10.3 million. Net loss totaled $45.3 million, up from $8.3 million.
I-14%&s Int-90%&b P/B 10.27 P/S 11.32 C/Sh $1.70 P/C 5.09
ARNA: For the six months ended 6/30/02, revenues rose 15% to $10.1 million. Net loss totaled $13.8 million, up from $2.1 million.
I-18%&B Int-26%&b P/B 0.60 P/S 7.98 C/Sh $7.54 P/C 0.75
CALP: For the six months ended 6/30/02, sales fell 5% to $14.3 million. Net loss totaled $21.1 million, vs. an income of $20.2 million.
I-8% Int-62%&S P/B 0.46 P/S 2.97 C/Sh $5.69 P/C 0.62
CRA: For the fiscal year ended 6/30/02, sales rose 35% to $120.9 million. Net loss increased 14% to $211.8 million.
I- 1% Int-58%&B P/B 0.55 P/S 4.62 C/Sh $12.53 P/C 0.67
CRGN: For the six months ended 6/02, revenues fell 29% to $8.5 million. Net loss totaled $41.7 million, up from $15.6 million.
I-18%&b Int-46%&S P/B 0.54 P/S 8.46 C/Sh $9.30 P/C 0.38
CRXL: For the six months ended 6/30/02, revenues totaled EUR5.0 million, up from EUR2.2 million. Net loss fell 10% to EUR11.4 million.
I-31% Int-3% P/B 0.69 P/S 9.78 C/Sh $3.16 P/C 0.93
CTIC: For the six months ended 6/30/02, revenues rose 61% to $4.5 million. Net loss applicable to Common rose 81% to $50 million.
I-37% Int-72%%S P/B 3.32 P/S 19.46 C/Sh $5.83 P/C 0.77
CVAS: For the six months ended 6/30/02, revenues decreased 55% to $73 thousand. Net loss fell 24% to $10.6 million.
I-10%&B Int-73%&B P/B 0.39 P/S 162.33 C/Sh $2.86 P/C 0.46
DDDP: For the six months ended 6/30/02, revenues rose 2% to $12.7 million. Net loss rose from $4.7 million to $16 million.
I-59% Int-45%&b P/B 0.82 P/S 2.24 C/Sh $3.67 P/C 0.79
DOVP: For the six months ended 6/30/02, revenues rose 29% to $1.3 million. Net loss totaled $7.7 million, up from $3.6 million.
I-62% Int-44%&B P/B 1.35 P/S 11.03 C/Sh $4.66 P/C 0.987
DYAX: For the six months ended 6/30/02, total revenues rose 28% to $19.5 million. Net loss totaled $14.8 million, up from $7.2 million.
I-24%&b Int-40%&B P/B 0.57 P/S 0.64 C/Sh $2.00 P/C 0.61
ELN: For the six months ended 6/30/02, revenues rose 2% to $906.5 million. Net loss totalled $752 million, vs. a profit of $210.7 million.
I-2% Int-52%&s P/B 0.18 P/S 0.25 C/Sh $5.82 P/C 0.223
EMIS: For the six months ended 6/30/02, revenues fell 38% to $1.8 million. Net loss rose from $19.8 million to $46.3 million.
I-5% Int-60%&S P/B 0.79 P/S 20.04 C/Sh $3.48 P/C 1.17
GNSC: For the six months ended 6/30/02, revenues rose 83% to $3.8 million. Net loss decreased 8% to $22.5 million.
I-36%&b Int-29%&B P/B 0.33 P/S 1.71 C/Sh $ 1.85 P/C 0.286
IMGN: For the fiscal year ended 6/30/02, revenues rose 31% to $5.9 million. Net loss before accounting change rose 53% to $14.6 million.
I-1% Int-30%&S P/B 0.89 P/S 20.08 C/Sh $3.43 P/C 0.87
INCY: For the six months ended 6/30/02, revenues fell 46% to $58.1 million. Net loss before acct. change rose 38% to $31 million.
I-25%&b Int-70%&b P/B 0.56 P/S 1.31 C/Sh $7.05 P/C 0.475
INGN: For the comparable six months ended 6/30/02, total revenues increased 88% to $551 thousand. Net loss increased 23% to $14.8 million.
I-61%&bs Int-22%&b P/B 1.20 P/S 42.95 C/Sh $1.71 P/C 0.99
INMX: For the six months ended 6/30/02, revenues fell 47% to $7.5 million. Net loss rose 75% to $14.1 million.
I-74%&s Int-31%&s P/B 0.58 P/S 1.77 C/Sh $2.01 P/C 0.66
INSM: For the six months ended 6/30/02, revenues rose 2% to $172 thousand. Net loss fell 30% to $13.2 million.
I-9%&b Inst-26%&S P/B 0.26 P/S 39.67 C/Sh $ 1.09 P/C 0.33
KDUS: For the six months ended 6/02, revenues remained flat at $100 thousand. Net loss totaled $260 thousand vs. an income of $108 thousand.
I-9%&b Int-26%&S P/B 0.58 P/S 24.32 C/Sh $1.83 P/C 0.61
LEON: For the three months ended 6/30/02, revenues fell 16% to EUR7.5 million. Net loss increased 71% to EUR19.2 million.
I-40% Int-40%&S P/B 0.34 P/S 1.68 C/Sh $5.13 P/C 0.65
MAXM: For the nine months ended 6/30/02, revenues decreased 28% to $1.8 million. Net loss before accounting change decreased 14% to $25 million.
I-1%&b Int-19%&s P/B 0.39 P/S 19.44 C/Sh $4.97 P/C 0.43
MEDX: For the six months ended 6/30/02, revenues increased 10% to $18.9 million. Net loss totalled $63.8 million vs. income of $7.6 million.
I-2% Int-69%&b P/B 0.56 P/S 5.50 C/Sh $5.44 P/C 0.60
NGEN: For the six months ended 6/30/02, revenues fell 38% to $3.5 million. Net loss fell 11% to $16.1 million.
I-42%&b Int-28%&s P/B 0.62 P/S 4.09 C/Sh $2.36 P/C 0.72
OGSI: For the six months ended 6/30/02, revenues fell 34% to L5.8 million. Net loss before U.S.GAAP totalled L19.5 million, up from L7.2 million.
I-1% Int-1%&B P/B 0.47 P/S 7.83 C/Sh $ 4.28 P/C 0.54
OSIP: For the nine months ended 6/30/02, revenues decreased 12% to $17.2 million. Net loss before acct. change totaled $196.3 million, up from $6.4 million.
I-2%&bs Int-92%&b P/B 1.30 P/S 21.88 C/Sh $14.28 P/C 1.00
PRCS: For the six months ended 6/30/02, revenues fell 82% to $1 million. Net loss rose 8% to $26.9 million.
I-10% Int-74%&b P/B 0.52 P/S 24.45 C/Sh $ 4.60 P/C 0.54
RZYM: For the six months ended 6/30/02, total revenues fell 29% to $3.2 million. Net loss applicable to Common fell 20% to $18.1 million.
I-39%&b Int-25%&B P/B 0.18 P/S 0.64 C/Sh $1.08 P/C 0.222
SGMO: For the six months ended 6/30/02, total revenues decreased 56% to $867 thousand. Net loss rose 81% to $8.1 million.
I-69%&s Int-39%&B P/B 0.57 P/S 11.37 C/Sh $2.24 P/C 0.785
SQNM: For the six months ended 6/30/02, revenues rose 41% to $17.8 million. Net loss before acct. change rose 62% to $25.4 million.
I-5%&b Int-24%&b P/B 0.34 P/S 1.44 C/Sh $ 2.94 P/C 0.51
TTP: For the six months ended 6/30/02, revenues fell 28% to $2.5 million. Net loss rose 89% to $12 million.
I-3%&bs Int-47%&s P/B 0.55 P/S 13.22 C/Sh $3.24 P/C 0.53
VGNX: For the six months ended 6/30/02, revenues fell 57% to $864 thousand. Net loss rose from $9.3 million to $19.7 million.
I-46% Int-33%&b P/B 0.29 P/S 10.75 C/Sh $2.68 P/C 0.313
VICL: For the six months ended 6/02, revenues fell 6% to $4 million. Net loss rose 95% to $10.2 million.
I-0%&s Int-45%&b P/B 0.46 P/S 5.45 C/Sh $6.14 P/C 0.49
VPHM: For the six months ended 6/30/02, revenues totaled $13.8 million, up from $2.5 million. Net loss applicable to Common fell 7% to $38.2 million.
I-50%&b Int-50%&s P/B 67.70 P/S 1.41 C/Sh $8.83 P/C 0.11
Bernard |
